NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/27/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization150.64 mln
Float12.74 mln
Earnings Date08/11/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
38.80
Transformational upside
Relative Strength
2
/ 100
Severely lagging
Debt / Equity
0.01
Debt-free
ROE
-69.96
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Corbus Pharmaceuticals is a clinical-stage company based in Norwood, Massachusetts, focused on developing new treatments for cancer and obesity. Its two lead programs include an antibody-based therapy designed to target and destroy cancer cells, and a weight-loss drug candidate engineered to reduce appetite without affecting the brain. Founded in 2009, the company is working to advance both treatments through clinical development.
